Entries by LRuas

Gadeta Appoints Scientific Advisory Board and Provides Business Update

/in

Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta B.V. (‘Gadeta’), an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors, today announced the formation of a Scientific Advisory Board comprised of internationally renowned leaders in oncology, T cell biology and strategic drug development. The Scientific […]

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform

/in

Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

/in

 STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3  STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022  20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is […]

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

/in

Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 Triple mode of action dengue fever program identified for development Industry veteran with exceptional leadership experience to support ExeVir’s new progressive pipeline against infectious diseases  Ghent, Belgium, 20 Oct 2022: ExeVir is developing robust therapies providing broad protection […]

AMSilk Relocate Offices to Support Expansion Plans

/in

The purpose-built offices will support its production of game-changing material solutions on an industrial scale Expanding biotech laboratory, pilot plants and office space, AMSilk embarks on the next stage of its journey to provide biofabricated silk materials across the world Munich, Germany, 10 October 2022 – AMSilk GmbH (“AMSilk”), a world leader in supplying innovative high-performance […]

© Optimum Strategic Communications.